Cargando…

Lack of SF3B1 R625 mutations in cutaneous melanoma

BACKGROUND: Melanoma is a deadly disease affecting people worldwide. Genetic studies have identified different melanoma subtypes characterized by specific recurrently mutated genes and led to the successful clinical introduction of targeted therapies. Hotspot mutations in SF3B1 were recently reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Schilling, Bastian, Bielefeld, Nicola, Sucker, Antje, Hillen, Uwe, Zimmer, Lisa, Schadendorf, Dirk, Zeschnigk, Michael, Griewank, Klaus G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671181/
https://www.ncbi.nlm.nih.gov/pubmed/23694694
http://dx.doi.org/10.1186/1746-1596-8-87
_version_ 1782271940778524672
author Schilling, Bastian
Bielefeld, Nicola
Sucker, Antje
Hillen, Uwe
Zimmer, Lisa
Schadendorf, Dirk
Zeschnigk, Michael
Griewank, Klaus G
author_facet Schilling, Bastian
Bielefeld, Nicola
Sucker, Antje
Hillen, Uwe
Zimmer, Lisa
Schadendorf, Dirk
Zeschnigk, Michael
Griewank, Klaus G
author_sort Schilling, Bastian
collection PubMed
description BACKGROUND: Melanoma is a deadly disease affecting people worldwide. Genetic studies have identified different melanoma subtypes characterized by specific recurrently mutated genes and led to the successful clinical introduction of targeted therapies. Hotspot mutations in SF3B1 were recently reported in uveal melanoma. Our aim was to see if these mutations also occur in cutaneous melanoma. FINDINGS: We analyzed a cohort of 85 cutaneous melanoma including 22 superficial spreading, 24 acral-lentiginous, 36 nodular, and 3 lentigo-maligna melanomas. Exon 14 of SF3B1, containing the site of recurrent mutations described in uveal melanoma, was sequenced in all samples. Additionally, NRAS exon 1 and 2 and BRAF exon 15 were sequenced in all, KIT exons 9, 11, 13, 17, and 18 in 30 samples. High numbers of BRAF and NRAS mutations were identified with frequencies varying according to melanoma subtype. None of the samples were found to harbor a SF3B1 mutation. CONCLUSIONS: We conclude that recurrent mutations in codon 625 of SF3B1 as reported in uveal melanoma are not present in most types of cutaneous melanoma. This highlights the genetic differences between cutaneous and uveal melanoma and the need for subtype specific therapeutic approaches.
format Online
Article
Text
id pubmed-3671181
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36711812013-06-05 Lack of SF3B1 R625 mutations in cutaneous melanoma Schilling, Bastian Bielefeld, Nicola Sucker, Antje Hillen, Uwe Zimmer, Lisa Schadendorf, Dirk Zeschnigk, Michael Griewank, Klaus G Diagn Pathol Short Report BACKGROUND: Melanoma is a deadly disease affecting people worldwide. Genetic studies have identified different melanoma subtypes characterized by specific recurrently mutated genes and led to the successful clinical introduction of targeted therapies. Hotspot mutations in SF3B1 were recently reported in uveal melanoma. Our aim was to see if these mutations also occur in cutaneous melanoma. FINDINGS: We analyzed a cohort of 85 cutaneous melanoma including 22 superficial spreading, 24 acral-lentiginous, 36 nodular, and 3 lentigo-maligna melanomas. Exon 14 of SF3B1, containing the site of recurrent mutations described in uveal melanoma, was sequenced in all samples. Additionally, NRAS exon 1 and 2 and BRAF exon 15 were sequenced in all, KIT exons 9, 11, 13, 17, and 18 in 30 samples. High numbers of BRAF and NRAS mutations were identified with frequencies varying according to melanoma subtype. None of the samples were found to harbor a SF3B1 mutation. CONCLUSIONS: We conclude that recurrent mutations in codon 625 of SF3B1 as reported in uveal melanoma are not present in most types of cutaneous melanoma. This highlights the genetic differences between cutaneous and uveal melanoma and the need for subtype specific therapeutic approaches. BioMed Central 2013-05-21 /pmc/articles/PMC3671181/ /pubmed/23694694 http://dx.doi.org/10.1186/1746-1596-8-87 Text en Copyright © 2013 Schilling et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Schilling, Bastian
Bielefeld, Nicola
Sucker, Antje
Hillen, Uwe
Zimmer, Lisa
Schadendorf, Dirk
Zeschnigk, Michael
Griewank, Klaus G
Lack of SF3B1 R625 mutations in cutaneous melanoma
title Lack of SF3B1 R625 mutations in cutaneous melanoma
title_full Lack of SF3B1 R625 mutations in cutaneous melanoma
title_fullStr Lack of SF3B1 R625 mutations in cutaneous melanoma
title_full_unstemmed Lack of SF3B1 R625 mutations in cutaneous melanoma
title_short Lack of SF3B1 R625 mutations in cutaneous melanoma
title_sort lack of sf3b1 r625 mutations in cutaneous melanoma
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671181/
https://www.ncbi.nlm.nih.gov/pubmed/23694694
http://dx.doi.org/10.1186/1746-1596-8-87
work_keys_str_mv AT schillingbastian lackofsf3b1r625mutationsincutaneousmelanoma
AT bielefeldnicola lackofsf3b1r625mutationsincutaneousmelanoma
AT suckerantje lackofsf3b1r625mutationsincutaneousmelanoma
AT hillenuwe lackofsf3b1r625mutationsincutaneousmelanoma
AT zimmerlisa lackofsf3b1r625mutationsincutaneousmelanoma
AT schadendorfdirk lackofsf3b1r625mutationsincutaneousmelanoma
AT zeschnigkmichael lackofsf3b1r625mutationsincutaneousmelanoma
AT griewankklausg lackofsf3b1r625mutationsincutaneousmelanoma